Sunitinib-impurities | Pharmaffiliates

sunitinib

An oral anti cancer drug. Works by inhibiting cellular signals by targeting multiple receptor tyrosine kinases (RTKs). Sunitinib is approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) Reference standards of Sunitinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Sunitinib N-Glucuronide
    [catalogue_number] => PA 19 75670
    [category_ids] => ,70,78,82,95,
    [chemical_name] => 
    [weight] => 574.61
    [form] => C28H35FN4O8
    [cas] => NA
    [pslug] => sunitinib-n-glucuronide-pa1975670
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 19 75670

Sunitinib N-Glucuronide


  • Catalogue No.:PA 19 75670

  • CAS :

    NA

  • Molecular Formula : C28H35FN4O8

  • Molecular Weight : 574.61